SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity

Mona Farhadipour(KU Leuven), Inge Depoortere(Vanderbilt University), Ellen Deleus, Theo Thijs(KU Leuven), Mathias Clarysse(KU Leuven), Kathrin Liszt(KU Leuven), Laurens J. Ceulemans(KU Leuven), Matthias Lannoo(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bart Van der Schueren(KU Leuven), Kaline Arnauts(Rega Institute for Medical Research)

iScience

November 23, 2023

10.1016/j.isci.2023.108517

Cited by 42

Related Papers

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

|The Lancet|2017|449

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

|The Lancet|2022|383

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

|The Lancet|2022|312

Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly

|Experimental Gerontology|2009|195